<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2022.868216</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Diagnostic value of dual-layer spectral detector CT in differentiating lung adenocarcinoma from squamous cell carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mu</surname>
<given-names>Ronghua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meng</surname>
<given-names>Zhuoni</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1426505"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Zixuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1322584"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qin</surname>
<given-names>Xiaoyan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Guangyi</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Xuri</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Peng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deng</surname>
<given-names>Meimei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiaodi</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhu</surname>
<given-names>Xiqi</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1414239"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Radiology, Graduate School of Guilin Medical University</institution>, <addr-line>Guilin</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Radiology, Nanxishan Hospital of Guangxi  Zhuang Autonomous Region</institution>, <addr-line>Guilin</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Philips (China) Investment Co., Ltd., Chengdu Branch</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ryogo Minamimoto, National Center For Global Health and Medicine, Japan</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Xiaohu Li, First Affiliated Hospital of Anhui Medical University, China; Asli Suner, Ege University, Turkey</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Xiqi Zhu, <email xlink:href="mailto:xiqi.zhu@163.com">xiqi.zhu@163.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>12</volume>
<elocation-id>868216</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>11</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Mu, Meng, Guo, Qin, Huang, Yang, Jin, Yang, Deng, Zhang and Zhu</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Mu, Meng, Guo, Qin, Huang, Yang, Jin, Yang, Deng, Zhang and Zhu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background and objective</title>
<p>The pathological type of non&#x2013;small cell lung cancer is considered to be an important factor affecting the treatment and prognosis. The purpose of this study was to investigate the diagnostic value of spectral parameters of dual-layer spectral detector computed tomography (DLCT) in determining efficacy to distinguish adenocarcinoma (AC) and squamous cell carcinoma (SC), and their combined diagnostic efficacy was also analyzed.</p>
</sec>
<sec>
<title>Methods</title>
<p>This is a single-center prospective study, and we collected 70 patients with lung SC and 127 patients with lung AC confirmed by histopathological examination. Morphological parameters, plain scan CT value, biphasic enhanced CT value, and spectral parameters were calculated. The diagnostic efficiency of morphological parameters, spectral parameters, and spectral parameters combined with morphological parameters was obtained by statistical analysis.</p>
</sec>
<sec>
<title>Results</title>
<p>In univariate analysis, seven morphological CT features differed significantly between SC and AC: tumor location (distribution), lobulation, spicule, air bronchogram, vacuole sign, lung atelectasis and/or obstructive pneumonia, and vascular involvement (all <italic>p</italic> &lt; 0.05). In the arterial phase and the venous phase, the spectral parameters of AC were higher than those of SC (AP-Zeff: 8.07 &#xb1; 0.23 vs. 7.85 &#xb1; 0.16; AP-ID: 1.41 &#xb1; 0.47 vs. 0.94 &#xb1; 0.28; AP-NID: 0.13 &#xb1; 0.04 vs. 0.09 &#xb1; 0.03; AP-&#x3bb;: 3.42 &#xb1; 1.10 vs. 2.33 &#xb1; 0.96; VP-Zeff: 8.26 &#xb1; 0.23 vs. 7.96 &#xb1; 0.16; VP-ID: 1.18 &#xb1; 0.51 vs. 1.16 &#xb1; 0.30; VP-NID: 0.39 &#xb1; 0.13 vs. 0.29 &#xb1; 0.08; VP-&#x3bb;: 4.42 &#xb1; 1.28 vs. 2.85 &#xb1; 0.72; <italic>p</italic> &lt; 0.001). When conducting multivariate analysis combining CT features and DLCT parameters with the best diagnostic efficacy, the independent predictors of AC were distribution on peripheral (OR, 4.370; 95% CI, 1.485&#x2013;12.859; p = 0.007), presence of air bronchogram (OR, 5.339; 95% CI, 1.729&#x2013;16.484; p = 0.004), and presence of vacuole sign ( OR, 7.330; 95% CI, 1.030&#x2013;52.184; p = 0.047). Receiver operating characteristic curves of the SC and AC showed that VP-&#x3bb; had the best diagnostic performance, with an area under the curve (AUC) of 0.864 and sensitivity and specificity rates of 85.8% and 74.3%, respectively; the AUC was increased to 0.946 when morphological parameters were combined, and sensitivity and specificity rates were 89.8% and 87.1%, respectively.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The quantitative parameters of the DLCT spectrum are of great value in the diagnosis of SC and AC, and the combination of morphological parameters and spectral parameters is helpful to distinguish SC from AC.</p>
</sec>
</abstract>
<kwd-group>
<kwd>lung cancer</kwd>
<kwd>pathological classification</kwd>
<kwd>dual layer detector</kwd>
<kwd>energy spectrum</kwd>
<kwd>X-ray computed tomography</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="29"/>
<page-count count="11"/>
<word-count count="5157"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Lung cancer is a disease that seriously affects human health. Approximately 85% of patients are non&#x2013;small cell lung cancer (NSCLC), of which adenocarcinoma (AC) and squamous cell carcinoma (SC) are the most common subtypes (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Histological classification of lung cancer has been demonstrated as an independent prognostic indicator. Because there are significant differences in biological behavior, treatment strategies and prognostic evaluation between different pathological subtypes of lung cancer (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>), a reasonable choice of treatment strategies can reduce mortality, prolong the survival time, and improve the quality of life.</p>
<p>Chest CT is the preferred imaging examination for the diagnosis of lung cancer. Traditional CT can evaluate the benign and malignant lesions according to their morphological features, intensity, and lymph node metastasis. However, it is difficult to evaluate the pathological subtypes of lung cancer because of the lack of quantitative indicators. If morphological criteria did not help to distinguish benign from malignant lung lesions, then it is strongly dependent on invasive pathologic examination or follow-up studies (<xref ref-type="bibr" rid="B5">5</xref>). As a non-invasive and effective pathological classification method of lung cancer, energy spectrum CT has become a hot spot in clinical research. The basic structure of the new generation of spectral CT is similar to that of ordinary CT, but it has two spatially equivalent detectors: the upper layer only absorbs low-energy photons, whereas the lower layer absorbs high-energy photons. On the premise of a perfect match in time and space within the projected data domain, high-energy and low-energy data can be parsed to obtain both traditional CT images and spectral images (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>Previous studies on energy spectrum CT in SC and AC are insufficient and controversial. Fehrenbach et&#xa0;al. (<xref ref-type="bibr" rid="B8">8</xref>) considered that only normalized iodine density (NID) in the arterial phase (AP) was significant for the differential diagnosis of NSCLC. Wang et&#xa0;al. (<xref ref-type="bibr" rid="B9">9</xref>) showed that the slope of the spectral curve (&#x3bb;) of 40 to 70 keV and iodine density (ID) in AP had diagnostic value in differentiating SC from AC, but the venous phase (VP) parameters were not included in the study. In contrast, Li et&#xa0;al. (<xref ref-type="bibr" rid="B10">10</xref>) showed that VP-ID can differentiate SC from AC by reflecting tumor microvessel density. Jia et&#xa0;al. (<xref ref-type="bibr" rid="B11">11</xref>) showed that AP-&#x3bb; (40&#x2013;100), AP-Zeff, AP-ID, and VP-ID were significant for their identification, but these data of SC were greater than that of AC. Problems, such as single-phase scanning, single spectral parameters, and the exclusion of morphological parameters, have caused a lot of controversies.</p>
<p>This study improves the above issues. The purpose of this study was to investigate the diagnostic value of spectral parameters of DLCT in determining efficacy to distinguish AC and SC, and their combined diagnostic efficacy was also analyzed.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Patients</title>
<p>A prospective study was conducted in our hospital between 1 August 2020 and 31 March 2021; a total of 656 consecutive patients who were diagnosed with lung cancer, confirmed by histopathological examination, were enrolled for the present study. To ensure the reliability of the results, all patients were required to conduct DLCT scan within 7 days before treatment. Inclusion criteria were as follows: (1) patients who underwent dual-layer detector spectral CT before treatment; (2) imaging, clinical, and pathological data were complete; (3) the short diameter of the tumor was greater than 2.0 cm; (4) no clinical antineoplastic treatment was given before enrollment; (5) patients can undergo the CT scan with the breath-holding; and (6) no other cancer history. Exclusion criteria were as follows: (1) patients with hyperthyroidism were not cured; (2) history of allergy to iodine contrast medium; and (3) complication of the heart, liver, kidney, and other important organ damage. The flow diagram of the present study is shown in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Study flowchart for the inclusion and exclusion criteria of the lung cancer patient sample.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-868216-g001.tif"/>
</fig>
<p>This single-center prospective study was approved by the Hospital Institution Review Committee [no. 2020(KY-E-30)], and written informed consent was obtained from all of the participants.</p>
</sec>
<sec id="s2_2">
<title>CT examination</title>
<p>All scans were performed using the IQon Spectral CT device (Philips Healthcare). The scans included routine CT plain film and AP and VP enhancement scan of the lung. The field of vision ranges from apex to diaphragm level. The contrast agent iophorol (70 ml of iopromide; Beijing Beilu Pharmaceutical Co., Ltd.) was administered <italic>via</italic> an antecubital vein at an intended flow rate of 3.0 ml/s with a high-pressure syringe, followed by 30 ml of saline, injected at the same flow rate. Scans were performed using the bolus chase method. The region of interest (ROI) was located in the descending aorta with a trigger threshold of 150 Hu. AP was started at 6 s after contrast agent injection, and VP was performed at 36 s after contrast agent injection. Parameters included tube voltages of 120 kVp, spectral CT adaptive current, collimator width of 64 &#xd7; 0.625 mm, pitch of 1.234, rotation time of 0.27 s, and matrix of 512 &#xd7; 512. After the scans were completed, the data obtained in the enhanced double phases were reconstructed by projected spatial-spectral reconstruction (spectral, level 4). The image reconstruction image thickness was 1 mm, and the image spacing was 1 mm.</p>
</sec>
<sec id="s2_3">
<title>Imaging analysis</title>
<p>The images were sent to the Philips Spectral Diagnostic Suite 9.0 (Philips Healthcare) workstation, and all data were processed and analyzed by two radiologists with more than 5 years of chest CT diagnosis experience. They were blinded to any patient&#x2019;s clinical data to mitigating potential cognitive biases. Three consecutive image sections containing the maximum cross section of the tumor and the adjacent upper and lower levels were chosen for measurement; the round or oval ROI was drawn as large as possible (areas close to half to two-thirds of the lesion area) to minimize the influences of noise and the partial volume effect. Two radiologists first sketched the ROI on the conventional CT enhanced and unenhanced images, and the morphological parameters (including location, diameter, margin, internal, and other features) of the tumor were evaluated. The ROI was placed on solid regions of the tumor, avoiding areas with vessels, calcification, cystic, and necrotic change. They then obtained data from other parameter images [spectral CT-mono energetic (40 and 60 keV), Z effective (Zeff) images, ID images, etc.], and copy/paste functions were used to ensure the consistency of the size, shape, and position of the ROIs. Enhancement value was defined as the difference of the CT value (AP/VP) and plain CT value according to the following formula: enhancement value (AP/VP) = CT value (AP/VP) &#x2212; plain CT value. To minimize the influence of the individual circulation status and scanning times, the ID values of lung lesions were normalized to that of the aorta in the aortopulmonary window level to calculate the NID: NID = ID/ID<sub>aorta</sub>. The slope of the spectral curve was defined as the difference of the CT value at 40 and 60 keV divided by the energy difference (60 &#x2212; 40) according to the following formula: &#x3bb; = [CT<sub>(40)</sub> &#x2212; CT<sub>(60)</sub>]/(60 &#x2212; 40).</p>
</sec>
<sec id="s2_4">
<title>Histochemical examination</title>
<p>Tumor specimens were analyzed by a pathologist with 14 years of immunohistochemical staining experience. Without knowing clinical information and spectral CT results, the pathologist numbered and evaluated all sections and analyzed and recorded their pathological types. The histologic criteria used for diagnosis were in accordance with the World Health Organization Classification of Lung Tumors (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>).</p>
</sec>
<sec id="s2_5">
<title>Statistical analysis</title>
<p>Kappa and  Intraclass correlation coefficient (ICC) tests were used to test the consistency of the measurement results of the two radiologists, with Kappa &gt; 0.8 or ICC &gt; 0.7 indicating satisfaction. All parameters were finally averaged over the measurements made by the two physicians. The normal distribution of all measured data was tested by the Shapiro&#x2013;Wilk test. Measurements that follow a normal distribution were expressed as mean (standard deviation). In addition, the counting data were expressed by n (%). Independent sample t-test was adopted for all measurement parameters, and the chi-square test was adopted for counting data. For parameters that were significantly different, the results of the pathological examination were used as the gold standard, receiver operating characteristic (ROC) curves were drawn, and the diagnostic efficiency of each parameter is analyzed. First, univariate analysis regression model was established to analyze the correlation between morphological parameters and SC and AC. Then, multivariate logistic regression analyses were applied to identify independent predictors of SC or AC, with the model of CT features alone and CT features combined with optimal spectral parameters; factors with <italic>p</italic> &lt; 0.05 on univariate analysis were used as the input variables for multiple logistic regression analysis, with the final model selected with the forward selection; model I (CT morphological parameters), model II (optimal spectral parameters), model III (morphological parameters and CT enhancement value), and model IV (morphological parameters and optimal spectral parameters) were established respectively. Finally, the ROC curves of the above models are drawn, and their diagnostic efficiency is analyzed. In the case of two-tailed <italic>p</italic>-value &lt; 0.05, the difference was considered statistically significant.</p>
<p>All data were analyzed using SPSS 21.0.0 (IBM Corp., Armonk, NY, USA), and graphics were drawn using GraphPad Prism version 9.0.2 (GraphPad software Inc., San Diego, USA).</p>
<p>We conducted an <italic>a priori</italic> power analysis to test the adequacy of our sample size to independent sample t-test using G*Power (<xref ref-type="bibr" rid="B26">26</xref>). We specified an alpha level of 0.05, a 1-&#x3b2; error probability of 0.80, and an effect size (f = 0.50) for an estimated medium effect. The results of the analysis suggested a total recommended sample size of 128. A <italic>post-hoc</italic> power analysis revealed that a sample size of 197 (lung AC : SC = 27:70) resulted in a reported power of 0.917 to detect a medium effect (f = 0.50) with an alpha level of 0.05.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Patients&#x2019; information</title>
<p>Eleven patients with poor image quality, 45 patients with lymph nodes and/or distant metastases, 32 patients with focal necrosis greater than one-half of the maximum cross-sectional area, and 60 patients without pathological findings or with previous treatment were excluded. Finally, a total of 197 patients met the inclusion criteria, including 70 patients with SC (male patients, 91.4%) and 127 patients with AC patients (male patients, 52.8%). The clinical data are shown in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Patient characteristics.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Variable</th>
<th valign="top" align="center">AC</th>
<th valign="top" align="center">SC</th>
<th valign="top" align="center">Statistic</th>
<th valign="top" align="center">
<italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">No. of patients</td>
<td valign="top" align="center">127</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Age, mean (SD)</td>
<td valign="top" align="center">63.8 (9.5)</td>
<td valign="top" align="center">62.5 (8.4)</td>
<td valign="top" align="center">&#x2212;0.969</td>
<td valign="top" align="center">0.334</td>
</tr>
<tr>
<td valign="top" align="left">Man</td>
<td valign="top" align="center">64.4 (9.0)</td>
<td valign="top" align="center">63.2 (8.1)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Woman</td>
<td valign="top" align="center">63.3 (10.2)</td>
<td valign="top" align="center">55.0 (8.2)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Sex, n (%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">30.294</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Male</td>
<td valign="top" align="center">67 (52.8)</td>
<td valign="top" align="center">64 (91.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Female</td>
<td valign="top" align="center">60 (47.2)</td>
<td valign="top" align="center">6 (8.6)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Diagnostic technique, n (%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">9.164</td>
<td valign="top" align="center">0.010</td>
</tr>
<tr>
<td valign="top" align="left">Transbronchial biopsy</td>
<td valign="top" align="center">11 (8.7)</td>
<td valign="top" align="center">17 (24.3)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">CT-guided biopsy</td>
<td valign="top" align="center">49 (38.6)</td>
<td valign="top" align="center">24 (34.3)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Surgery</td>
<td valign="top" align="center">67 (52.8)</td>
<td valign="top" align="center">29 (41.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AC, adenocarcinoma; SC, squamous cell carcinoma.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_2">
<title>CT characteristics of the SC and AC</title>
<p>Univariate analysis revealed that seven CT features differed significantly between SC and AC in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>: tumor location (distribution), lobulation, spicule, air bronchogram, vacuole sign, lung atelectasis and/or obstructive pneumonia, and vascular involvement (all <italic>p</italic> &lt; 0.05). AC was more frequently found in the periphery, and the lobulation, spicule, air bronchogram, and vacuole sign were more likely to be observed among AC. Tumors with lung atelectasis and/or obstructive pneumonia and vascular involvement were more likely to be observed among SC. When it came to other CT features, no significant differences were noted between AC and SC. <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref> shows the traditional CT quantitative parameters, and there was no significant difference in CT values during plain scan. AP-CT value of AC was higher than that of SC, and AP-enhancement value of AC was higher than that of SC. The VP-CT value of AC was higher than that of SC, and the VP-enhancement value of AC was higher than that of SC.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Morphological parameters in patients with AC and SC.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Characteristics</th>
<th valign="top" align="center">AC</th>
<th valign="top" align="center">SC</th>
<th valign="top" align="center">
<italic>P</italic>-value</th>
<th valign="top" align="center">Univariate OR (95% CI)</th>
<th valign="top" align="center">
<italic>P</italic>-value</th>
<th valign="top" align="center">Multivariable OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="7" align="left">
<bold>Location, n (%)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Distribution</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center">
<bold>0.007</bold>
</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Peripheral</td>
<td valign="top" align="center">83 (65.4)</td>
<td valign="top" align="center">12 (17.1)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">9.117 (4.433, 18.751)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">4.370 (1.485-12.859)</td>
</tr>
<tr>
<td valign="top" align="left">Central</td>
<td valign="top" align="center">44 (34.6)</td>
<td valign="top" align="center">58 (89.2)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">Reference</td>
<td valign="top" align="center"/>
<td valign="top" align="center">Reference</td>
</tr>
<tr>
<td valign="top" colspan="7" align="left">
<bold>Lobe location</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Right upper lobe</td>
<td valign="top" align="center">27 (21.3)</td>
<td valign="top" align="center">10 (14.3)</td>
<td valign="top" align="center">0.525</td>
<td valign="top" align="center">1.440 (0.468, 4.430)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Right middle lobe</td>
<td valign="top" align="center">33 (26.0)</td>
<td valign="top" align="center">17 (24.3)</td>
<td valign="top" align="center">0.948</td>
<td valign="top" align="center">1.035 (0.366, 2.925)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Right lower lobe</td>
<td valign="top" align="center">23 (18.1)</td>
<td valign="top" align="center">16 (22.9)</td>
<td valign="top" align="center">0.626</td>
<td valign="top" align="center">0.767 (0.263, 2.234)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Left upper lobe</td>
<td valign="top" align="center">29 (22.8)</td>
<td valign="top" align="center">19 (27.1)</td>
<td valign="top" align="center">0.697</td>
<td valign="top" align="center">0.814 (0.289, 2.291)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Left lower lobe</td>
<td valign="top" align="center">15(11.8)</td>
<td valign="top" align="center">8 (11.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">Reference</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="7" align="left">
<bold>Diameter, mean (SD)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Long-axis diameter (cm)</td>
<td valign="top" align="center">4.28 (1.67)</td>
<td valign="top" align="center">4.73 (1.92)</td>
<td valign="top" align="center">0.087</td>
<td valign="top" align="center">0.867 (0.736, 1.021)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Short-axis diameter (cm)</td>
<td valign="top" align="center">3.00 (1.55)</td>
<td valign="top" align="center">3.19 (1.31)</td>
<td valign="top" align="center">0.394</td>
<td valign="top" align="center">0.918 (0.755, 1.117)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="7" align="left">
<bold>Margin, n (%)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Contour (Irregular)</td>
<td valign="top" align="center">59 (46.5)</td>
<td valign="top" align="center">41 (58.6)</td>
<td valign="top" align="center">0.105</td>
<td valign="top" align="center">0.614 (0.340, 1.107)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Border definition (poorly)</td>
<td valign="top" align="center">65 (51.2)</td>
<td valign="top" align="center">46 (65.7)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Lobulation (Y)</td>
<td valign="top" align="center">76 (59.8)</td>
<td valign="top" align="center">30 (42.9)</td>
<td valign="top" align="center">
<bold>0.023</bold>
</td>
<td valign="top" align="center">1.987 (1.100, 3.590)</td>
<td valign="top" align="center">0.528</td>
<td valign="top" align="center">1.406 (0.448&#x2013;4.049)</td>
</tr>
<tr>
<td valign="top" align="left">Spicule (Y)</td>
<td valign="top" align="center">71 (55.9)</td>
<td valign="top" align="center">25 (35.7)</td>
<td valign="top" align="center">
<bold>0.007</bold>
</td>
<td valign="top" align="center">2.282 (1.251, 4.164)</td>
<td valign="top" align="center">0.198</td>
<td valign="top" align="center">2.037 (0.690&#x2013;6.017)</td>
</tr>
<tr>
<td valign="top" colspan="7" align="left">
<bold>Internal, n (%)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Air bronchogram (Y)</td>
<td valign="top" align="center">73 (57.5)</td>
<td valign="top" align="center">22 (31.4)</td>
<td valign="top" align="center">
<bold>0.001</bold>
</td>
<td valign="top" align="center">2.949 (1.594, 5.456)</td>
<td valign="top" align="center">
<bold>0.004</bold>
</td>
<td valign="top" align="center">5.339 (1.729&#x2013;16.484)</td>
</tr>
<tr>
<td valign="top" align="left">Vacuole sign (Y)</td>
<td valign="top" align="center">28 (22.0)</td>
<td valign="top" align="center">3 (4.3)</td>
<td valign="top" align="center">
<bold>0.003</bold>
</td>
<td valign="top" align="center">6.316 (1.846, 21.618)</td>
<td valign="top" align="center">
<bold>0.047</bold>
</td>
<td valign="top" align="center">7.330 (1.030&#x2013;52.184)</td>
</tr>
<tr>
<td valign="top" align="left">Vessel convergence (Y)</td>
<td valign="top" align="center">86 (67.7)</td>
<td valign="top" align="center">44 (62.9)</td>
<td valign="top" align="center">0.491</td>
<td valign="top" align="center">1.239 (0.673, 2.284)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Liquefactive necrosis (Y)</td>
<td valign="top" align="center">51 (40.2)</td>
<td valign="top" align="center">36 (51.4)</td>
<td valign="top" align="center">0.128</td>
<td valign="top" align="center">0.643 (0.352, 1.141)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Calcification (Y)</td>
<td valign="top" align="center">15 (11.8)</td>
<td valign="top" align="center">15 (21.4)</td>
<td valign="top" align="center">0.076</td>
<td valign="top" align="center">0.491 (0.224, 1.077)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="7" align="left">
<bold>Other, n (%)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Pleural indentation (Y)</td>
<td valign="top" align="center">54 (42.5)</td>
<td valign="top" align="center">23 (32.9)</td>
<td valign="top" align="center">0.185</td>
<td valign="top" align="center">1.512 (0.821, 2.783)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Mediastinal/hilar lymphadenopathy (Y)</td>
<td valign="top" align="center">60 (47.2)</td>
<td valign="top" align="center">25 (35.7)</td>
<td valign="top" align="center">0.119</td>
<td valign="top" align="center">1.612 (0.884, 2.938)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Lung atelectasis and/or obstructive pneumonia (Y)</td>
<td valign="top" align="center">11 (8.7)</td>
<td valign="top" align="center">16 (22.9)</td>
<td valign="top" align="center">
<bold>0.007</bold>
</td>
<td valign="top" align="center">0.320 (0.139, 0.736)</td>
<td valign="top" align="center">0.536</td>
<td valign="top" align="center">1.778 (0.287&#x2013;11.003)</td>
</tr>
<tr>
<td valign="top" align="left">Vascular involvement (Y)</td>
<td valign="top" align="center">12 (9.4)</td>
<td valign="top" align="center">22 (31.4)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
<td valign="top" align="center">0.228 (0.104, 0.497)</td>
<td valign="top" align="center">
<bold>0.047</bold>
</td>
<td valign="top" align="center">5.121 (1.018&#x2013;25.749)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AC, adenocarcinoma; SC, squamous cell carcinoma; Y, yes.</p>
</fn>
<fn>
<p>Values in bold indicate statistical significance, p &lt; 0.05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Conventional CT enhancement values and spectral parameters in patients with AC and SC.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">AC</th>
<th valign="top" align="center">SC</th>
<th valign="top" align="center">t-value</th>
<th valign="top" align="center">
<italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>Plain CT value, mean (SD)</bold>
</td>
<td valign="top" align="center">34.12 (12.75)</td>
<td valign="top" align="center">30.07 (13.10)</td>
<td valign="top" align="center">0.545</td>
<td valign="top" align="center">0.586</td>
</tr>
<tr>
<td valign="top" colspan="5" align="left">
<bold>AP, mean (SD)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">AP-CT value (Hu)</td>
<td valign="top" align="center">76.37 (12.17)</td>
<td valign="top" align="center">67.43 (11.67)</td>
<td valign="top" align="center">5.006</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">AP-enhancement value (Hu)</td>
<td valign="top" align="center">40.44 (9.02)</td>
<td valign="top" align="center">34.36 (15.22)</td>
<td valign="top" align="center">3.520</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Zeff</td>
<td valign="top" align="center">8.07 (0.23)</td>
<td valign="top" align="center">7.85 (0.16)</td>
<td valign="top" align="center">8.024</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">ID</td>
<td valign="top" align="center">1.41 (0.47)</td>
<td valign="top" align="center">0.94 (0.28)</td>
<td valign="top" align="center">8.683</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">NID</td>
<td valign="top" align="center">0.13 (0.04)</td>
<td valign="top" align="center">0.09 (0.03)</td>
<td valign="top" align="center">5.482</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">&#x3bb;</td>
<td valign="top" align="center">3.42 (1.10)</td>
<td valign="top" align="center">2.33 (0.69)</td>
<td valign="top" align="center">8.579</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="5" align="left">
<bold>VP, mean (SD)</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">VP-CT value (Hu)</td>
<td valign="top" align="center">87.47 (14.60)</td>
<td valign="top" align="center">75.03 (11.55)</td>
<td valign="top" align="center">6.148</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">VP-enhancement value (Hu)</td>
<td valign="top" align="center">51.54 (12.94)</td>
<td valign="top" align="center">41.95 (16.51)</td>
<td valign="top" align="center">4.504</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Zeff</td>
<td valign="top" align="center">8.26 (0.23)</td>
<td valign="top" align="center">7.96 (0.16)</td>
<td valign="top" align="center">10.962</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">ID</td>
<td valign="top" align="center">1.78 (0.51)</td>
<td valign="top" align="center">1.16 (0.30)</td>
<td valign="top" align="center">10.859</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">NID</td>
<td valign="top" align="center">0.39 (0.13)</td>
<td valign="top" align="center">0.29 (0.08)</td>
<td valign="top" align="center">7.354</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">&#x3bb;</td>
<td valign="top" align="center">4.42 (1.28)</td>
<td valign="top" align="center">2.85 (0.72)</td>
<td valign="top" align="center">11.009</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AC, adenocarcinoma; SC, squamous cell carcinoma; AP, arterial phase; VP, venous phase; Zeff, effective atomic number; ID, iodine density; NID, normalized iodine density; &#x3bb;, the slope of spectral curve.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_3">
<title>CT spectral quantitative parameters of the SC and AC</title>
<p>As shown in <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>, all CT spectral parameters in the AC group in both the arterial and venous phases were higher than in the SC group (P&lt;0.001).</p>
</sec>
<sec id="s3_4">
<title>Diagnostic implication</title>
<p>Because spectral quantitative parameters have statistically significant differences between SC and AC in the AP and the VP, diagnostic capacity was assessed using ROC curves in <xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref> and <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>. The spectral parameters in VP are generally better than those in AP in differentiating SC from AC. The VP-&#x3bb; has the best diagnostic efficacy, with AUC = 0.864, 95% CI = 0.813~0.915, sensitivity = 85.8%, and specificity = 74.3%.</p>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Performance of differential parameters in distinguishing the AC and SC in the receiver operating characteristic analysis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Parameter</th>
<th valign="top" align="center">AUC</th>
<th valign="top" align="center">Thresholds</th>
<th valign="top" align="center">Sensitivity (%)</th>
<th valign="top" align="center">Specificity (%)</th>
<th valign="top" align="center">95% CI</th>
<th valign="top" align="center">
<italic>P-</italic>value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="7" align="left">
<bold>AP</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">CT value</td>
<td valign="top" align="center">0.704</td>
<td valign="top" align="center">69.47</td>
<td valign="top" align="center">72.4</td>
<td valign="top" align="center">64.3</td>
<td valign="top" align="center">0.692~0.779</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">CT enhancement value</td>
<td valign="top" align="center">0.721</td>
<td valign="top" align="center">36.50</td>
<td valign="top" align="center">63.8</td>
<td valign="top" align="center">75.7</td>
<td valign="top" align="center">0.641~0.802</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Zeff</td>
<td valign="top" align="center">0.798</td>
<td valign="top" align="center">7.975</td>
<td valign="top" align="center">71.7</td>
<td valign="top" align="center">82.9</td>
<td valign="top" align="center">0.735~0.860</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">ID</td>
<td valign="top" align="center">0.811</td>
<td valign="top" align="center">1.145</td>
<td valign="top" align="center">71.7</td>
<td valign="top" align="center">82.9</td>
<td valign="top" align="center">0.737~0.864</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">NID</td>
<td valign="top" align="center">0.753</td>
<td valign="top" align="center">0.110</td>
<td valign="top" align="center">68.5</td>
<td valign="top" align="center">74.3</td>
<td valign="top" align="center">0.683~0.823</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">&#x3bb;</td>
<td valign="top" align="center">0.808</td>
<td valign="top" align="center">2.800</td>
<td valign="top" align="center">71.7</td>
<td valign="top" align="center">84.3</td>
<td valign="top" align="center">0.747~0.869</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="7" align="left">
<bold>VP</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">CT value</td>
<td valign="top" align="center">0.760</td>
<td valign="top" align="center">82.13</td>
<td valign="top" align="center">69.3</td>
<td valign="top" align="center">78.6</td>
<td valign="top" align="center">0.691~0.828</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">CT enhancement value</td>
<td valign="top" align="center">0.733</td>
<td valign="top" align="center">48.65</td>
<td valign="top" align="center">65.4</td>
<td valign="top" align="center">81.4</td>
<td valign="top" align="center">0.656~0.811</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Zeff</td>
<td valign="top" align="center">0.862</td>
<td valign="top" align="center">8.055</td>
<td valign="top" align="center">82.7</td>
<td valign="top" align="center">75.7</td>
<td valign="top" align="center">0.810~0.913</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">ID</td>
<td valign="top" align="center">0.857</td>
<td valign="top" align="center">1.265</td>
<td valign="top" align="center">83.5</td>
<td valign="top" align="center">74.3</td>
<td valign="top" align="center">0.805~0.909</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">NID</td>
<td valign="top" align="center">0.787</td>
<td valign="top" align="center">0.297</td>
<td valign="top" align="center">79.5</td>
<td valign="top" align="center">65.7</td>
<td valign="top" align="center">0.721~0.852</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">&#x3bb;</td>
<td valign="top" align="center">0.864</td>
<td valign="top" align="center">3.088</td>
<td valign="top" align="center">85.8</td>
<td valign="top" align="center">74.3</td>
<td valign="top" align="center">0.813~0.915</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AP, arterial phase; VP, venous phase; Zeff, effective atomic number; ID, iodine density; NID, normalized iodine density; &#x3bb;, the slope of spectral curve.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>ROC curves for dual-layer spectral detector CT quantitative parameters between squamous cell carcinoma and adenocarcinoma in the arterial phase <bold>(A)</bold> and the venous phase <bold>(B)</bold>. In the arterial phase <bold>(A)</bold>, the ID has the best diagnostic efficiency; AUC, 0.811; sensitivity and specificity, 71.7% and 82.9%, respectively; in the venous phase <bold>(B)</bold>, the &#x3bb; has the best diagnostic efficiency; AUC, 0.864; sensitivity and specificity, 85.8% and 74.3%, respectively. AP, arterial phase; VP, venous phase; Zeff, effective atomic number; ID, iodine density; NID, normalized iodine density; &#x3bb;, slope of 40- to 60-keV spectral curve.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-868216-g002.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>Multivariable analysis and joint diagnostic efficiency</title>
<p>In multivariate analysis, after adjusting for other confounding factors, models of distribution, air bronchus, vacuole sign, and VP-&#x3bb; are associated with AC (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Forest plot of multivariable regression analysis of dual-layer spectral detector CT metrics combined with CT features predicting adenocarcinoma from squamous cell carcinoma.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-868216-g003.tif"/>
</fig>
<p>As shown in <xref ref-type="table" rid="T5">
<bold>Table&#xa0;5</bold>
</xref> and <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>, ROC curve analysis in diagnosing of the AC and SC using morphological parameters, optimum spectral parameter (VP-&#x3bb;), combining morphological parameters with CT value, and combining morphological parameters with spectral parameters in the VP. When morphological parameters were combined with VP-&#x3bb;, the diagnostic efficiency is the highest, with AUC = 0.946, 95% CI = 0.917&#x2013;0.975, sensitivity = 89.8%, and specificity = 87.1%.</p>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>Different models in distinguishing the AC and SC in the receiver operating characteristic analysis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Parameter</th>
<th valign="top" align="center">AUC</th>
<th valign="top" align="center">Thresholds</th>
<th valign="top" align="center">Sensitivity (%)</th>
<th valign="top" align="center">Specificity (%)</th>
<th valign="top" align="center">95% CI</th>
<th valign="top" align="center">
<italic>P-</italic>value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Model I</td>
<td valign="top" align="center">0.863</td>
<td valign="top" align="center">&#x2014;</td>
<td valign="top" align="center">83.5</td>
<td valign="top" align="center">71.4</td>
<td valign="top" align="center">0.813~0.914</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Model II</td>
<td valign="top" align="center">0.864</td>
<td valign="top" align="center">3.088</td>
<td valign="top" align="center">85.8</td>
<td valign="top" align="center">74.3</td>
<td valign="top" align="center">0.813~0.915</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Model III</td>
<td valign="top" align="center">0.899</td>
<td valign="top" align="center">&#x2014;</td>
<td valign="top" align="center">73.2</td>
<td valign="top" align="center">88.6</td>
<td valign="top" align="center">0.857~0.941</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Model IV</td>
<td valign="top" align="center">0.946</td>
<td valign="top" align="center">&#x2014;</td>
<td valign="top" align="center">89.8</td>
<td valign="top" align="center">87.1</td>
<td valign="top" align="center">0.917~0.975</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Model I, morphological parameters; Model II, &#x3bb; in the venous phase; Model III, combination of morphology and CT value in the venous phase; Model IV, combination of morphology and &#x3bb; in the venous phase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>The quantitative parameters of different models were used to identify the lung adenocarcinoma from squamous cell carcinoma. The combination of morphology and &#x3bb; in the venous phase has the greatest diagnostic efficiency; AUC, 0.946; sensitivity and specificity, 89.8% and 87.1%, respectively. Model I, morphological parameters; Model II;, &#x3bb; in the venous phase; Model III, combination of morphology and CT value in the venous phase; Model IV, combination of morphology and &#x3bb; in the venous phase.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-868216-g004.tif"/>
</fig>
<p>
<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref> shows the imaging and pathological images.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>(1) CT images and the pathological section of a 58-year-old man with squamous cell carcinoma in the venous phase <bold>(A&#x2013;D)</bold> and a 63-year-old man with adenocarcinoma in the venous phase <bold>(a&#x2013;d)</bold>. Iodine density images <bold>(A, a)</bold>; Z-effective images <bold>(B, b)</bold>; the dashed box point to lung cancer tissue. Magnification: C, &#xd7;600; slope of spectral curve in the arterial phase; the horizontal axis represents the energy (keV), and the vertical axis represents mean attenuation (Hu) <bold>(D, d)</bold>. &#x3bb; = 1.72, ID = 0.70, NID = 0.19, and Zeff = 7.71 for squamous cell carcinoma, and &#x3bb; = 3.91, ID = 1.59, NID = 0.31, and Zeff = 8.19 for adenocarcinoma. Significant differences were observed in all parameters representing these cases.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-868216-g005.tif"/>
</fig>
</sec>
<sec id="s3_6">
<title>Reliability of measurements</title>
<p>For all the given parameters, the Kappa and ICC tests found that the measurement results were found to be consistent between the two radiologists (<italic>p</italic> &gt; 0.05).</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Our results showed that the spectral parameters of the VP have a higher diagnostic value in differentiating SC from AC than those of the AP. Morphological parameters also have important diagnostic value, in which distribution, air bronchus, and vacuole sign are associated with AC. The joint diagnosis efficacy is higher than that of single index, and the joint diagnosis of spectral parameters and morphological parameters had the best efficacy. Therefore, the combined diagnosis of energy spectral parameters and morphological parameters is more effective and instructive for the pathological classification of lung cancer.</p>
<p>CT is widely used in the diagnosis of lung diseases. In recent years, spectral CT has become a hot spot in the study of lung cancer. However, in diagnostic studies of lung cancer (<xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>), most researchers were keen to study the optimal diagnostic performance of quantitative parameters, ignoring the morphological features. Therefore, we have supplemented the study of the morphological features of tumors. Our results suggest that the morphological features of tumors can be used for histological inference of AC and SC, although some of the signs are not significant. Several previous studies have compared the clinical and imaging features of lung cancer of different pathological types. Chu et&#xa0;al. (<xref ref-type="bibr" rid="B14">14</xref>) showed that the radiologic and microscopic findings correlate well with each other and are closely associated with tumour prognosis. Understanding their morphological features is helpful for early identification and diagnosis. Wang et&#xa0;al. (<xref ref-type="bibr" rid="B15">15</xref>) have shown that AC and SC have different clinical and imaging characteristics and that imaging features are useful for differential diagnosis. Koenigkam et&#xa0;al. (<xref ref-type="bibr" rid="B16">16</xref>) found that SC more likely to occur in male patients, more frequently found in the central distribution, and less lobulation, burr, and air bronchogram. In addition, previous studies did not analyze the contrast enhancement between AC and SC, but we did a detailed analysis. We found the differences between them and verified the diagnostic value of morphological features.</p>
<p>Conventional CT is used to differentiate subtypes of tumors by their size, shape, and attenuation value. Although it has some advantages, the accuracy of diagnosis is still limited (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B17">17</xref>). The spectral parameters provide quantitative analysis for histological diagnosis of NSCLC, and its accuracy is higher than that of conventional CT, making up for the deficiency of conventional CT. There are several reasons: i. From the perspective of histology, AC is a malignant epithelial neoplasm of glandular differentiation, in which glandular tubular and glandular luminal&#x2013;like structures are common, and it contains more microvessels with abundant blood supply (<xref ref-type="bibr" rid="B18">18</xref>). Whereas, SC is defined as keratinized malignant epithelial tumor, which mostly grows in a stacked pattern, and its internal structure is dense, with frequent tumor nests, keratinized beads, and intercellular bridges, and the internal part is mostly accompanied by liquefactive necrosis (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). ii. The degree of tumor enhancement depends only on the amount of contrast medium in the tumor vessels. The central type of lung cancer is mainly SC, mainly supplied by bronchial artery, whereas the peripheral type of lung cancer is mainly AC with dual blood supply of bronchial artery and pulmonary artery (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Because the blood supply from the bronchial artery is later than that from the pulmonary artery, the VP better reflects the blood supply of the tumor.</p>
<p>ID reflects intravascular blood flow distribution and vascular status by quantitative analysis of iodine content, but it is influenced by many factors, including cardiac output and blood volume of the patient, concentration and flow rate of the contrast medium, and dose and rate of injection (<xref ref-type="bibr" rid="B20">20</xref>). NID was defined as the ratio of tumor ID to that of the aorta or subclavian arteries at the same level, and most researchers (<xref ref-type="bibr" rid="B8">8</xref>,&#xa0;<xref ref-type="bibr" rid="B21">21</xref>&#x2013;<xref ref-type="bibr" rid="B23">23</xref>) state that NID can reduce the effect of individual circulatory variability on tumor iodine content and thus more accurately reflect the blood supply of the lesion. However, in this comparison of AC and SC, we found that ID is more effective than NID in both the AP and the VP, which is consistent with the results of the study by Li et&#xa0;al. (<xref ref-type="bibr" rid="B10">10</xref>). This suggests that NID depends on the extent of lesion and aortic enhancement, and changes in aortic ID may cause NID to deviate.</p>
<p>Energy spectrum curve is the curve of material decay varying with x-ray energy, which reflects the decay characteristics of material. Theoretically, each substance has its own specific spectrum curve, and the slope of the spectrum curve decreases with the expansion of its range (<xref ref-type="bibr" rid="B24">24</xref>). The K edge of iodine is 33.2 keV, so the lower the keV, the higher the CT value (<xref ref-type="bibr" rid="B25">25</xref>). From IQon, monochrome images of the 40- to 200-keV energy range can be obtained. However, not all images can be used to observe and diagnose lesions, because image quality varies at different energy levels. Low&#x2013;kilo&#x2013;electron volt images can improve tissue enhancement, increase tissue contrast, and make the display of small lesions clearer. Equivalent kilo&#x2013;electron volt images can reduce image noise and improve image quality. This study shows that VP-&#x3bb; is conducive to the differentiation of lung SC and AC. Jia et&#xa0;al. (<xref ref-type="bibr" rid="B9">9</xref>) reported that the spectral parameters of SC in the AP and the VP were larger than those of AC, and this is different from our experimental results.</p>
<p>Zeff is the atomic number of an element that has the same decay coefficient as a compound or mixture and can be used to identify the tissue composition of a substance, especially in substances with similar CT values. It is a quantitative indicator of different substances (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B26">26</xref>). Moreover, Zeff can indirectly provide information about the accumulation of contrast media (<xref ref-type="bibr" rid="B27">27</xref>). Previous studies have shown that Zeff can identify substances (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). In the differential diagnosis between AC and SC, Zeff in VP was greater than that in AP. This is related to the blood supply of the tumors described above, their histological characteristics, the growth pattern of the tumors, and the changes of their surrounding microenvironment.</p>
<p>In this study, we provide not only quantitative parameters for tumor enhancement but also qualitative parameters for morphological features. The diagnostic ability of combining morphological features with quantitative parameters, especially DLCT, has been significantly improved, which confirms the additional diagnostic value of quantitative analysis of spectral parameters. Although there are more and more studies on quantitative data, CT morphology of lung cancer remains an important indicator of cancer diagnosis. On the one hand, they are closely related to the growth characteristics of tumors and easy to collect. On the other hand, in the era of precision medicine and big data, a single spectral parameter may also be considered unreliable.</p>
<p>The limitations of this study are as follows: (1) because of the small sample size, this study failed to stratify the degree of differentiation of tumors; (2) unenhanced spectral parameters were not included in the study; (3) not all pathological sections were matched with imaging ROI; and (4) some patients&#x2019; unenhanced images were replaced by virtual unenhanced images, which may affect our results.</p>
<p>In summary, the combination of morphological features and DLCT spectral parameters improved the diagnostic efficiency in distinguishing SC from AC. This may help clinicians develop initial treatment strategy and prognostic predictions. Although relatively accurate pathological diagnosis can be obtained by invasive methods, complications or patient intolerance still exist.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by Nanxishan Hospital of Guangxi Zhuang Autonomous Region Institution Review Committee [NO.2020(KY-E-30)]. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>First author: RM. Co-author: ZM; ZG. Other authors: XQ; GH; XY; HJ; PY; MD; XDZ. Guarantor and correspondent: XQZ. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8" sec-type="acknowledgment">
<title>Acknowledgments</title>
<p>The authors thank the dedicated this project participants, their loved ones, and the devoted staff and trainees who contributed to recruitment, screening, and enrollment of the cohort.</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>Author XZ is employed by Philips China Investment Co.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>PRR11 induces filopodia formation and promotes cell motility <italic>via</italic> recruiting ARP2/3 complex in non-small cell lung cancer cells</article-title>. <source>Genes Dis</source> (<year>2021</year>) <volume>9</volume>(<issue>1</issue>):<page-range>230&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.gendis.2021.02.012</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sung</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ferlay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Siegel</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Laversanne</surname> <given-names>M</given-names>
</name>
<name>
<surname>Soerjomataram</surname> <given-names>I</given-names>
</name>
<name>
<surname>Jemal</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source> (<year>2021</year>) <volume>71</volume>(<issue>3</issue>):<page-range>209&#x2013;49</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>XQ</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>TT</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: A population-based study</article-title>. <source>Transl Lung Cancer Res</source> (<year>2019</year>) <volume>8</volume>(<issue>4</issue>):<page-range>367&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/tlcr.2019.08.16</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saijo</surname> <given-names>N</given-names>
</name>
<name>
<surname>Niitani</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tominaga</surname> <given-names>K</given-names>
</name>
<name>
<surname>Eguchi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Koketsu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fujino</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung</article-title>. <source>J Cancer Res Clin Oncol</source> (<year>1980</year>) <volume>97</volume>(<issue>1</issue>):<page-range>71&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/BF00411280</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacMahon</surname> <given-names>H</given-names>
</name>
<name>
<surname>Naidich</surname> <given-names>DP</given-names>
</name>
<name>
<surname>Goo</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Leung</surname> <given-names>ANC</given-names>
</name>
<name>
<surname>Mayo</surname> <given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for management of incidental pulmonary nodules detected on CT images: From the fleischner society 2017</article-title>. <source>Radiology</source> (<year>2017</year>) <volume>284</volume>(<issue>1</issue>):<page-range>228&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.2017161659</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kikano</surname> <given-names>EG</given-names>
</name>
<name>
<surname>Rajdev</surname> <given-names>M</given-names>
</name>
<name>
<surname>Salem</surname> <given-names>KZ</given-names>
</name>
<name>
<surname>Laukamp</surname> <given-names>K</given-names>
</name>
<name>
<surname>Felice</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Gilkeson</surname> <given-names>RC</given-names>
</name>
<etal/>
</person-group>. <article-title>Utility of iodine density perfusion maps from dual-energy spectral detector CT in evaluating cardiothoracic conditions: A primer for the radiologist</article-title>. <source>AJR Am J Roentgenol</source> (<year>2020</year>) <volume>214</volume>(<issue>4</issue>):<page-range>775&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2214/AJR.19.21818</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Hamersvelt</surname> <given-names>RW</given-names>
</name>
<name>
<surname>I&#x161;gum</surname> <given-names>I</given-names>
</name>
<name>
<surname>de Jong</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Cramer</surname> <given-names>MJM</given-names>
</name>
<name>
<surname>Leenders</surname> <given-names>GEH</given-names>
</name>
<name>
<surname>Willemink</surname> <given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Application of speCtraL computed tomogrAphy to impRove specIficity of cardiac compuTed tomographY (CLARITY study): Rationale and design</article-title>. <source>BMJ Open</source> (<year>2019</year>) <volume>9</volume>(<issue>3</issue>):<elocation-id>e025793</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmjopen-2018-025793</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehrenbach</surname> <given-names>U</given-names>
</name>
<name>
<surname>Kahn</surname> <given-names>J</given-names>
</name>
<name>
<surname>B&#xf6;ning</surname> <given-names>G</given-names>
</name>
<name>
<surname>Feldhaus</surname> <given-names>F</given-names>
</name>
<name>
<surname>Merz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Frost</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Spectral CT and its specific values in the staging of patients with non-small cell lung cancer: Technical possibilities and clinical impact</article-title>. <source>Clin Radiol</source> (<year>2019</year>) <volume>74</volume>(<issue>6</issue>):<page-range>456&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.crad.2019.02.010</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>K</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Preliminary application of high-definition computed tomographic gemstone spectral imaging in lung cancer</article-title>. <source>J&#xa0;Comput Assist Tomogr</source> (<year>2014</year>) <volume>38</volume>(<issue>1</issue>):<fpage>77</fpage>&#x2013;<lpage>81</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RCT.0b013e3182a21633</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Huo</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>FJ</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>TY</given-names>
</name>
</person-group>. <article-title>Spectral CT in lung cancer: Usefulness of iodine concentration for evaluation of tumor angiogenesis and prognosis</article-title>. <source>AJR Am J Roentgenol</source> (<year>2020</year>) <volume>215</volume>(<issue>3</issue>):<fpage>595</fpage>&#x2013;<lpage>602</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2214/AJR.19.22688</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>CT spectral parameters and serum tumour markers to differentiate histological types of cancer histology</article-title>. <source>Clin Radiol</source> (<year>2018</year>) <volume>73</volume>(<issue>12</issue>):<page-range>1033&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.crad.2018.07.104</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Travis</surname> <given-names>WD</given-names>
</name>
<name>
<surname>Brambilla</surname> <given-names>E</given-names>
</name>
<name>
<surname>Nicholson</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Yatabe</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Austin</surname> <given-names>JHM</given-names>
</name>
<name>
<surname>Beasley</surname> <given-names>MB</given-names>
</name>
<etal/>
</person-group>. <article-title>The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification</article-title>. <source>J Thorac Oncol</source> (<year>2015</year>) <volume>10</volume>(<issue>9</issue>):<page-range>1243&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/JTO.0000000000000630</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Travis</surname> <given-names>WD</given-names>
</name>
<name>
<surname>Brambilla</surname> <given-names>E</given-names>
</name>
<name>
<surname>Nicholson</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Yatabe</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Austin</surname> <given-names>JHM</given-names>
</name>
<etal/>
</person-group>. <article-title>The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification</article-title>. <source>J Thorac Oncol</source> (<year>2015</year>) <volume>10</volume>(<issue>9</issue>):<fpage>1243</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1097/JTO.0000000000000630</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname> <given-names>ZG</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>ZG</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>SS</given-names>
</name>
<etal/>
</person-group>. <article-title>Small peripheral lung adenocarcinoma: CT and histopathologic characteristics and prognostic implications</article-title>. <source>Cancer Imaging</source> (<year>2011</year>) <volume>11</volume>(<issue>1</issue>):<page-range>237&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1102/1470-7330.2011.0033</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical and radiological characteristics of central pulmonary adenocarcinoma: A comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response</article-title>. <source>Onco Targets Ther</source> (<year>2018</year>) <volume>11</volume>:<page-range>2509&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/OTT.S154385</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koenigkam Santos</surname> <given-names>M</given-names>
</name>
<name>
<surname>Muley</surname> <given-names>T</given-names>
</name>
<name>
<surname>Warth</surname> <given-names>A</given-names>
</name>
<name>
<surname>de Paula</surname> <given-names>WD</given-names>
</name>
<name>
<surname>Lederlin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schnabel</surname> <given-names>PA</given-names>
</name>
<etal/>
</person-group>. <article-title>Morphological computed tomography features of surgically resectable pulmonary squamous cell carcinomas: Impact on prognosis and comparison with adenocarcinomas</article-title>. <source>Eur J Radiol</source> (<year>2014</year>) <volume>83</volume>(<issue>7</issue>):<page-range>1275&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejrad.2014.04.019</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sui</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical utility of quantitative dual-energy CT iodine maps and CT morphological features in distinguishing small-cell from non-small-cell lung cancer</article-title>. <source>Clin Radiol</source> (<year>2019</year>) <volume>74</volume>(<issue>4</issue>):<page-range>268&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.crad.2018.10.012</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mairinger</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>[Histology, cytology and molecular diagnostics of lung cancer]</article-title>. <source>Pathologe</source> (<year>2019</year>) <volume>40</volume>(<issue>6</issue>):<page-range>649&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00292-019-00677-8</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Classification and pathology of lung cancer</article-title>. <source>Surg Oncol Clin N Am</source> (<year>2016</year>) <volume>25</volume>(<issue>3</issue>):<page-range>447&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.soc.2016.02.003</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milne</surname> <given-names>EN</given-names>
</name>
</person-group>. <article-title>Circulation of primary and metastatic pulmonary neoplasms. A postmortem microarteriographic study</article-title>. <source>Am J Roentgenol Radium Ther Nucl Med</source> (<year>1967</year>) <volume>100</volume>(<issue>3</issue>):<page-range>603&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2214/ajr.100.3.603</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>CT perfusion imaging can detect residual lung tumor early after radiofrequency ablation: A preliminary animal study on both tumoral and peri-tumoral region assessment</article-title>. <source>J Thorac Dis</source> (<year>2022</year>) <volume>14</volume>(<issue>1</issue>):<page-range>64&#x2013;76</page-range>. doi: <pub-id pub-id-type="doi">10.21037/jtd-21-967</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kono</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Solitary pulmonary nodules: Evaluation of blood flow patterns with dynamic CT</article-title>. <source>Radiology</source> (<year>1997</year>) <volume>205</volume>(<issue>2</issue>):<page-range>471&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiology.205.2.9356631</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Ai</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Spectral CT imaging of lung cancer: Quantitative analysis of spectral parameters and their correlation with tumor CharacteristIDs</article-title>. <source>AcademID Radiol</source> (<year>2018</year>) <volume>25</volume>(<issue>11</issue>):<page-range>1398&#x2013;404</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.acra.2018.04.017</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Suo</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>HW</given-names>
</name>
</person-group>. <article-title>Correlation between dual-energy spectral CT imaging parameters and pathological grades of non-small cell lung cancer</article-title>. <source>Clin Radiol</source> (<year>2018</year>) <volume>73</volume>(<issue>4</issue>):<page-range>412.e1&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.crad.2017.11.004</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulpe</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dierolf</surname> <given-names>M</given-names>
</name>
<name>
<surname>G&#xfc;nther</surname> <given-names>B</given-names>
</name>
<name>
<surname>Busse</surname> <given-names>M</given-names>
</name>
<name>
<surname>Achterhold</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gleich</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>K-Edge subtraction computed tomography with a compact synchrotron X-ray source</article-title>. <source>Sci Rep</source> (<year>2019</year>) <volume>9</volume>(<issue>1</issue>):<fpage>13332</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-019-49899-z</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodsitt</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Christodoulou</surname> <given-names>EG</given-names>
</name>
<name>
<surname>Larson</surname> <given-names>SC</given-names>
</name>
</person-group>. <article-title>Accuracies of the synthesized monochromatic CT numbers and effective atomic numbers obtained with a rapid kVp switching dual energy CT scanner</article-title>. <source>Med Phys</source> (<year>2011</year>) <volume>38</volume>(<issue>4</issue>):<page-range>2222&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1118/1.3567509</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deniffel</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sauter</surname> <given-names>A</given-names>
</name>
<name>
<surname>Fingerle</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rummeny</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Makowski</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Pfeiffer</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Improved differentiation between primary lung cancer and pulmonary metastasis by combining dual-energy CT-derived biomarkers with conventional CT attenuation</article-title>. <source>Eur Radiol</source> (<year>2021</year>) <volume>31</volume>(<issue>2</issue>):<page-range>1002&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-020-07195-9</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The value of nonenhanced single-source dual-energy CT for differentiating metastases from adenoma in adrenal glands</article-title>. <source>Acad Radiol</source> (<year>2015</year>) <volume>22</volume>(<issue>7</issue>):<page-range>834&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.acra.2015.03.004</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>G&#xfc;m&#xfc;&#x15f;ta&#x15f;</surname> <given-names>S</given-names>
</name>
<name>
<surname>Inan</surname> <given-names>N</given-names>
</name>
<name>
<surname>Akansel</surname> <given-names>G</given-names>
</name>
<name>
<surname>Cift&#xe7;i</surname> <given-names>E</given-names>
</name>
<name>
<surname>Demirci</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ozkara</surname> <given-names>SK</given-names>
</name>
</person-group>. <article-title>Differentiation of malignant and benign lung lesions with diffusion-weighted MR imaging</article-title>. <source>Radiol Oncol</source> (<year>2012</year>) <volume>46</volume>(<issue>2</issue>):<page-range>106&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2478/v10019-012-0021-3</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>